FindTrial
Sign In

Pioglitazone 45 mg

DRUG9 trials

Sponsors

Boehringer Ingelheim, The University of Texas Health Science Center at San Antonio, Milton S. Hershey Medical Center, University of Texas Southwestern Medical Center, Dasman Diabetes Institute

Conditions

Covid19DiabetesDiabetes Mellitus, Type 2HyperglycemiaLung CancerMyocardial Reperfusion InjuryNephrolithiasis, Uric AcidStroke, Acute

Phase 1

Pioglitazone Treatment for Hyperglycemic Acute Ischemic Stroke
TerminatedNCT04123067
Milton S. Hershey Medical CenterDiabetes, Hyperglycemia, Stroke, Acute
Start: 2020-09-01End: 2021-04-07Updated: 2022-09-15

Phase 2

The Neuroendocrine Effects of Pioglitazone in Patients With Cancer and Cachexia
Active, not recruitingNCT05919147
Pennington Biomedical Research CenterLung Cancer
Start: 2024-01-03End: 2026-06-30Target: 24Updated: 2025-07-04

Phase 3

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
CompletedNCT01183013
Boehringer IngelheimDiabetes Mellitus, Type 2
Start: 2010-08-31End: 2013-02-28Updated: 2014-10-20

Phase 4

Dapagliflozin Plus Pioglitazone in T1DM
RecruitingNCT03878459
The University of Texas Health Science Center at San AntonioType 1 Diabetes Mellitus
Start: 2019-08-08End: 2027-12-31Target: 120Updated: 2025-07-01
Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss
CompletedNCT04370093
University of Texas Southwestern Medical CenterNephrolithiasis, Uric Acid
Start: 2019-10-17End: 2025-05-28Updated: 2025-09-09
Effect of Pioglitazone on T2DM Patients With COVID-19
NCT04604223
Dasman Diabetes InstituteCovid19, Type 2 Diabetes
Start: 2021-01-18End: 2021-06-29Target: 1506Updated: 2021-03-17
The Role of Pioglitazone in Vascular Transcriptional Remodeling
RecruitingNCT05775380
University of Campinas, BrazilMyocardial Reperfusion Injury
Start: 2023-06-15End: 2024-12-22Target: 20Updated: 2024-01-12
Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?
Not yet recruitingNCT06922656
Dasman Diabetes InstituteType 1 Diabetes
Start: 2025-09-15End: 2027-01-15Target: 60Updated: 2025-08-29

Unknown Phase

Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes
RecruitingNCT05501483
Karolinska InstitutetType 2 Diabetes
Start: 2023-02-08End: 2032-12-31Target: 60Updated: 2025-02-26

Related Papers

Effect of pioglitazone on inflammatory response and clinical outcome in T2DM patients with COVID-19: a randomized multicenter double-blind clinical trial
Frontiers in Immunology2024-09-063 citations